Predicted to enable butyrate-CoA ligase activity; fatty acid ligase activity; and propionate CoA-transferase activity. Predicted to act upstream of or within fatty acid biosynthetic process. Predicted to be located in mitochondrial matrix. Used to study hypertension. Biomarker of ocular hypertension. Human ortholog(s) of this gene implicated in IgA glomerulonephritis. Orthologous to human ACSM3 (acyl-CoA synthetase medium chain family member 3); PARTICIPATES IN fatty acid beta degradation pathway; butanoate metabolic pathway; INTERACTS WITH 1-naphthyl isothiocyanate; 2,3,7,8-tetrachlorodibenzodioxine; 2,3,7,8-Tetrachlorodibenzofuran.
acyl-coenzyme A synthetase ACSM3, mitochondrial; butyrate--CoA ligase 3; butyryl coenzyme A synthetase 3; butyryl-coenzyme A synthetase 3; middle-chain acyl-CoA synthetase 3; propionate--CoA ligase; Sa; SA hypertension-associated homolog; SA rat hypertension-associated gene; SA rat hypertension-associated homolog; SA rat hypertension-associated protein; Sah; ssubA
[lard co-treated with Cholesterol and Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of ACSM3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSM3 mRNA
[Hydrocarbons and Chlorinated co-treated with Polychlorinated Biphenyls co-treated with methylmercuric chloride] results in decreased expression of ACSM3 mRNA
[lard co-treated with Cholesterol and Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of ACSM3 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSM3 mRNA
[lard co-treated with Cholesterol and Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of ACSM3 mRNA
[lard co-treated with Cholesterol and Dietary co-treated with Dietary Sucrose co-treated with Fructose co-treated with Glucose] results in decreased expression of ACSM3 mRNA
[Hydrocarbons and Chlorinated co-treated with Polychlorinated Biphenyls co-treated with methylmercuric chloride] results in decreased expression of ACSM3 mRNA
[Diethylnitrosamine co-treated with Clofibric Acid] affects the expression of SAH mRNA and [Diethylnitrosamine co-treated with Thioacetamide] results in decreased expression of SAH mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ACSM3 mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSM3 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSM3 mRNA
[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSM3 mRNA